Point72 Asset Management L.P. Has $8.51 Million Stock Holdings in Silence Therapeutics plc (NASDAQ:SLN)

Point72 Asset Management L.P. lifted its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN - Free Report) by 219.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467,800 shares of the company's stock after purchasing an additional 321,300 shares during the quarter. Point72 Asset Management L.P. owned 1.56% of Silence Therapeutics worth $8,505,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Parkman Healthcare Partners LLC grew its stake in Silence Therapeutics by 71.8% during the third quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company's stock worth $9,051,000 after buying an additional 208,029 shares in the last quarter. Ikarian Capital LLC increased its stake in Silence Therapeutics by 15.9% in the third quarter. Ikarian Capital LLC now owns 587,343 shares of the company's stock valued at $10,678,000 after acquiring an additional 80,678 shares during the last quarter. Janus Henderson Group PLC raised its position in Silence Therapeutics by 32.8% during the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock valued at $19,798,000 after purchasing an additional 268,250 shares in the last quarter. Eventide Asset Management LLC acquired a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $11,635,000. Finally, Verition Fund Management LLC acquired a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $207,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, November 15th. Chardan Capital reissued a "buy" rating and issued a $55.00 target price on shares of Silence Therapeutics in a report on Thursday, November 14th. Morgan Stanley reaffirmed an "overweight" rating and set a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. William Blair reissued an "outperform" rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, BMO Capital Markets reaffirmed an "outperform" rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $57.20.

Silence Therapeutics Price Performance

NASDAQ SLN traded up $0.37 during trading hours on Friday, reaching $8.52. The company's stock had a trading volume of 517,529 shares, compared to its average volume of 864,451. The firm has a fifty day simple moving average of $14.84 and a 200-day simple moving average of $17.60. Silence Therapeutics plc has a 52 week low of $5.81 and a 52 week high of $27.72. The stock has a market cap of $255.00 million, a P/E ratio of -5.43 and a beta of 1.05.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.